New hope for Tough-to-Treat blood cancers: first patients sought for groundbreaking drug trial
NCT ID NCT07294300
Summary
This is the first study in people for a new drug called QLS2313, designed for patients with advanced blood cancers like lymphoma or leukemia that have come back or stopped responding to other treatments. The main goal is to find a safe and tolerable dose by giving the drug to small groups of patients at increasing levels. Researchers will also look for early signs that the drug might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY HEMATOLOGICAL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Jiaotong University School of Medicine Ruijin Hospital
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.